Exicure, Inc. Stock: price and insider trades · United States

Exicure, Inc. (ticker: Nasdaq XCUR) is a United States-listed biotechnology company, quoted on the NASDAQ market in the United States and headquartered in Redwood City, California. For French-speaking investors, Exicure should be viewed as a highly speculative small-cap biotech with a materially evolving corporate profile rather than a conventional late-stage drug developer. The company was founded in 2011 and initially built its strategy around nucleic-acid therapeutics, with a research platform focused on RNA-targeting approaches against validated biological targets. In September 2022, however, Exicure disclosed a major workforce reduction, suspended preclinical activities, halted all R&D, and began exploring strategic alternatives to maximize shareholder value.

Following that restructuring, Exicure’s competitive positioning became that of a transitional biotech platform focused on monetizing and reworking legacy assets while rebuilding an operating base. Its historical assets have included cavrotolimod, a clinical-stage immuno-oncology program, and a preclinical SCN9A candidate for neuropathic pain. More recently, in 2025, the company acquired GPCR Therapeutics USA Inc., a clinical-stage biotechnology business whose lead program is being evaluated for stem cell mobilization in multiple myeloma, sickle cell disease, and potential support applications in cell and gene therapy. This acquisition marked a meaningful shift in the company’s operating structure and contributed to renewed research and development activity.